Free Trial

Centogene (CNTG) Stock Price, News & Analysis

0.00 (0.00%)
(As of 05/21/2024 ET)
Today's Range
50-Day Range
52-Week Range
44,103 shs
Average Volume
108,280 shs
Market Capitalization
P/E Ratio
Dividend Yield
Price Target

Centogene MarketRank™ Stock Analysis

Analyst Rating
Short Interest
0.33% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.22mentions of Centogene in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.67 out of 5 stars

CNTG stock logo

About Centogene Stock (NASDAQ:CNTG)

Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific. It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It operates through two segments: Pharmaceutical and Diagnostics. The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services. In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.

CNTG Stock Price History

CNTG Stock News Headlines

CENTOGENE Receives Nasdaq Non-Compliance Notice
Centogene (NASDAQ: CNTG)
Centogene NV: CENTOGENE Explores Strategic Alternatives
Centogene Explores Strategic Alternatives, Incl. Sale
Centogene Announces Receipt Of Nasdaq Notice Of Delisting
CENTOGENE Explores Strategic Alternatives
CENTOGENE Announces Preliminary Full Year 2023 Revenue
Centogene NV Ordinary Shares CNTG
See More Headlines
Receive CNTG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$52.53 million
Book Value
($1.01) per share


Free Float
Not Optionable
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Kim Stratton (Age 62)
    CEO & Member of Management Board
    Comp: $933.13k
  • Mr. Jose Miguel Coego Rios
    CFO, Legal & IT and Member of Management Board
  • Dr. Peter Bauer M.D. (Age 54)
    Chief Medical & Genomic Officer and Member of Management Board
    Comp: $186.41k
  • Dr. Andrin Oswald M.D. (Age 52)
    Ph.D., Advisor
    Comp: $943.96k
  • Mr. Ian Rentsch
    Chief Commercial Officer & GM of Pharma

CNTG Stock Analysis - Frequently Asked Questions

How have CNTG shares performed in 2024?

Centogene's stock was trading at $1.20 on January 1st, 2024. Since then, CNTG shares have decreased by 68.2% and is now trading at $0.3820.
View the best growth stocks for 2024 here

When is Centogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024.
View our CNTG earnings forecast

How were Centogene's earnings last quarter?

Centogene (NASDAQ:CNTG) announced its earnings results on Wednesday, November, 24th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.49. The firm earned $35.60 million during the quarter, compared to the consensus estimate of $31.91 million. During the same quarter last year, the company earned ($0.32) earnings per share.

What other stocks do shareholders of Centogene own?
When did Centogene IPO?

Centogene (CNTG) raised $60 million in an IPO on Thursday, November 7th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Evercore ISI acted as the underwriters for the IPO and Baird and BTIG were co-managers.

Who are Centogene's major shareholders?

Centogene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.00%).

How do I buy shares of Centogene?

Shares of CNTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTG) was last updated on 5/21/2024 by Staff

From Our Partners